Biotech | August 02, 2021
Windlas Biotech opens for subscription this week
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
Proceeds from the IPO will be used for the expansion of the Dehradun facility.
India business is growing as per projections; whereas US business will bounce back soon.
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
Turnover of API division of ISLL stood at Rs 856.58 crore
WHO prequalification enables the procurement of ROTAVAC 5D by UN agencies namely UNICEF and PAHO
Price band in the range of Rs 933 to Rs 954
The group now has 320 approvals and has so far filed over 400 ANDAs
The new greenfield manufacturing facility will be operated alongside the Guwahati facility as a parallel unit thereby helping mitigate the risks of a single-location operation
The company posted net profit of Rs.9.06 crores for the period ended June 30, 2020.
The company posted net profit of Rs.124.45 crores for the period ended June 30, 2020.
Subscribe To Our Newsletter & Stay Updated
